Technology
- HOME
- Technology
- Core Technologies
Tumoroid Biobank
Tumoroid Biobank
Tumoroid Biobank of OncoClew
- Establishment of best-in-class tumoroid biobank
- More than 1,000 patient-derived tumoroids from five types of most common cancers
- Possible to select a patient-derived tumoroid according to types of gene mutations and expression levels
The Partnership with Korean Best Hospitals
Tumoroid Biobank of OncoClew (2022.4)
* Continuous expanding the biobank sclae by securing additional tumoroids through partnerships with the Korean best hospitals
(Plan to secure additional brain tumor, breast cancer, and pancreatic cancer)
(Plan to secure additional brain tumor, breast cancer, and pancreatic cancer)
Tumoroid Biobank-based OncoClew’s Business Model
- ＂New anti-cancer drug and patient-specific drug evaluation service＂and ＂development of new anti-cancer drug＂ are in progress by the establishment of Oncoclew Biobank based on tumoroid and big data
